CARCIK CD123/33 for Refractory/Relapsed AML and BPDCN in Children and Adults

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
The purpose of this phase I/II clinical trial is to test CARCIK-CD123/33 cells to treat patients with R/R AML/BPDCN, who have otherwise exhausted conventional treatment options. In particular, this study will assess the safety and feasibility of CARCIK-CD123/33 cells infusion in adults and children with R/R AML, ahead of scheduled alloHCT.
Epistemonikos ID: fcb9c2ded852f80e9ffc0a9e3730487bc10b954d
First added on: Oct 17, 2026